LPL Financial LLC Has $7.78 Million Stock Position in United Therapeutics Corporation (NASDAQ:UTHR)

LPL Financial LLC grew its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 77.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,246 shares of the biotechnology company’s stock after purchasing an additional 11,007 shares during the period. LPL Financial LLC owned approximately 0.06% of United Therapeutics worth $7,783,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Anchor Investment Management LLC raised its holdings in shares of United Therapeutics by 12.0% in the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 30 shares during the last quarter. Hohimer Wealth Management LLC raised its holdings in shares of United Therapeutics by 0.3% in the 1st quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company’s stock worth $3,900,000 after acquiring an additional 37 shares during the last quarter. Applied Finance Capital Management LLC raised its holdings in shares of United Therapeutics by 3.7% in the 1st quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company’s stock worth $349,000 after acquiring an additional 40 shares during the last quarter. Dunhill Financial LLC raised its holdings in shares of United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 50 shares during the last quarter. Finally, Two Sigma Investments LP raised its holdings in shares of United Therapeutics by 3.0% in the 4th quarter. Two Sigma Investments LP now owns 1,773 shares of the biotechnology company’s stock worth $626,000 after acquiring an additional 52 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on UTHR shares. UBS Group lowered their target price on shares of United Therapeutics from $410.00 to $385.00 and set a “buy” rating on the stock in a report on Monday, June 30th. Wall Street Zen lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 2nd. Cantor Fitzgerald initiated coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They issued an “overweight” rating and a $405.00 price objective for the company. Wells Fargo & Company reduced their price objective on shares of United Therapeutics from $314.00 to $295.00 and set an “equal weight” rating for the company in a research report on Thursday, July 31st. Finally, JPMorgan Chase & Co. reduced their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research report on Tuesday, July 8th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $379.69.

United Therapeutics Stock Up 0.7%

United Therapeutics stock opened at $301.50 on Monday. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $417.82. The firm has a 50 day moving average price of $296.64 and a 200-day moving average price of $310.59. The company has a market capitalization of $13.60 billion, a P/E ratio of 11.77, a P/E/G ratio of 4.57 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same period in the prior year, the company earned $5.85 earnings per share. The firm’s revenue was up 11.7% on a year-over-year basis. Equities analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 12,000 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the completion of the transaction, the chief financial officer directly owned 8,118 shares of the company’s stock, valued at $2,641,353.66. This represents a 59.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard Giltner sold 3,036 shares of the company’s stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total transaction of $879,225.60. Following the sale, the director owned 19,384 shares in the company, valued at $5,613,606.40. The trade was a 13.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 81,681 shares of company stock valued at $24,618,359 over the last quarter. 10.30% of the stock is currently owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.